References
- American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;168: 818–900
- Stoller JK, Brantly M, Fleming LE, Bean JA, Walsh J, for the Alpha One Foundation Research Network Registry Investigators. Formation and current results of a patient-organized registry for α1-antitrypsin deficiency. Chest 2000;118(3):843–8
- Crystal RG, Brantly ML, Hubbard RC, Curiel DT, States DJ, Holmes MD. The alpha1-antitrypsin gene and its mutations. Clinical consequences and strategies for therapy. Chest 1989;95:196–208
- World Health Organization, Human Genetics Programme. Alpha-1-antitrypsin deficiency. Report of a WHO meeting, Geneva, 18–20 March 1996
- Laurell C-B, Eriksson S. The electrophoretic a-1-globulin pattern of serum in α-1 antitrypsin deficiency. Scand J Clin Lab Invest 1963;15: 132–40
- De Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002;122:1818–29
- Alpha-1 Foundation. A healthcare provider’s guide to alpha-1 antitrypsin deficiency [online]. Available from http://www.alphaone.org/documents/pdf/Alpha-1%20HCPG.pdf [accessed 23 March 2005]
- US Food and Drug Administration. Summary basis of approval. Aralast™ [online]. Available from http://www.fda.gov/cber/sba/alphalp122302S.pdf [accessed 23 March 2005]
- Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma α1-antitrypsin, Respitin. Chest 2002;122:66–74
- US Food and Drug Administration. Product approval information. Zemaira® [online]. Available from http://www.fda.gov/cber/approvltr/alphave070803L.htm [accessed 23 March 2005]
- ZLB Behring Data on File
- Abboud RT, Ford GT, Chapman KR. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome? Treat Respir Med 2005;4: 1–8
- Coan MH, Brockway WJ, Eguizabal H, Kreig T, Fournel M. Preparation and properties of alpha 1-proteinase inhibitor concentrate from human plasma. Vox Sang 1985;48: 333–2
- Aralast™ alpha1-proteinase inhibitor (human), full prescribing information, January 2003 [online]. Available from http://www.aralast.com/PDF/aralast_pi.pdf [accessed 23 March 2005]
- Prolastin® alpha1-proteinase inhibitor (human), full prescribing information, March 2003. Available from http://www.univgraph.com/bayer/inserts/prolastin.pdf [accessed 23 March 2005]
- Zemaira® alpha1-proteinase inhibitor (human), full prescribing information, December 2003 [online]. Available from http://www.zemaira.com/zCommon/zemairaPI.pdf [accessed 23 March 2005]
- Brantly M. Alpha 1-anti-trypsin genotypes and phenotypes. In: Crystal RG, editor. Lung biology in health and disease, vol. 88. Marcel Dekker, Inc; 1996. p. 47
- Mills K, Mills PB, Clayton PT, Johnson AW, Whitehouse DB, Winchester BG. Identification of α1-antitrypsin variants in plasma with the use of proteomic technology. Clin Chem 2001;47: 2012–22